Human stomach carcinoma-specific T cells derived from the tumour-draining lymph nodes. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Human stomach carcinoma-specific T cells derived from the tumour-draining lymph nodes.

Br J Cancer. 1994 Dec;70(6):1053-9. Unique Identifier : AIDSLINE MED/95071844
Stulle K; Vollmers HP; Marquardt P; Muller-Hermelink HK; Pathologisches Institut, Universitat Wurzburg, Germany.

Abstract: In this paper we investigate the reactivity pattern of T cells from stomach carcinoma patients against autologous tumour cells. T cells obtained from the tumour environment, tumour-draining lymph nodes and peripheral blood were cloned in 78 patients with stomach cancer and anti-tumour cytotoxic T lymphocytes (CTLs) precursor frequencies were assessed in each sample by using limiting dilution analysis. When tumour-specific CTLs were tested for specific T-cell killing by using only low doses of Interleukin 2 (100 U ml-1), a moderate rate of proliferation frequency of T cells (0.047) and specific cytotoxicity (12%) were observed in lymph node populations. When both IL-2 and autologous tumour cells in mixed lymphocyte tumour cultures (MLTCs) were used for stimulation, a dramatic increase in number (0.1) and in specific lytic activity (46%) could be measured. No effect or specific activity to tumour cells was observed with peripheral blood lymphocytes and tumour-infiltrating lymphocytes.
Keywords: Adult Aged Carcinoma/*IMMUNOLOGY Cytotoxicity, Immunologic CD4-CD8 Ratio CD4-Positive T-Lymphocytes/IMMUNOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY Female Human Immunity, Cellular Immunophenotyping Lymph Nodes/IMMUNOLOGY Lymphocyte Transformation Lymphocytes, Tumor-Infiltrating/IMMUNOLOGY Male Middle Age Stomach Neoplasms/*IMMUNOLOGY Support, Non-U.S. Gov't T-Lymphocyte Subsets/IMMUNOLOGY T-Lymphocytes, Cytotoxic/*IMMUNOLOGY JOURNAL ARTICLEKWDadultagedcarcinoma/
950330
M9530809

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .